FDA OKs RET Inhibitor for Lung, Thyroid Cancers

]]>(MedPage Today) -- WASHINGTON--The FDA approved selpercatinib (Retevmo) as the first specific treatment for metastatic non-small cell lung cancer (NSCLC) or thyroid cancer with rearranged during transfection (RET) gene fusions.A selective...